In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 9, 2006, Pages 3062-3069

  Kamoda, Osamu ^a,b,c   Anzai, Kinsei ^a   Mizoguchi, Jun Ichi ^a   Shiojiri, Masatoshi ^a   Yanagi, Toshiharu ^a   Nishino, Takeshi ^b   Kamiya, Shigeru ^c  

^a Nagase Chemtex Ltd   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; METRONIDAZOLE; TG 44; UNCLASSIFIED DRUG;

AEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ERADICATION THERAPY; GROWTH CURVE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PH; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AMOXICILLIN; BENZOATES; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; GUANIDINES; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR STRUCTURE;

EID: 33748676704     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00036-06     Document Type: Article

References (29)

1. American Digestive Health Foundation. 1997. The report of the Digestive Health Initiative SM International Update Conference on Helicobacter pylori. Gastroenterology 113(Suppl. 6):S4-S8.
2. Asaka, M., T. Sugiyama, M. Kato, K. Satoh, H. Kuwayama, Y. Fukuda, T. Fujioka, T. Takemoto, K. Kimura, T. Shimoyama, K. Shimizu, and S. Kobayashi. 2001. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6:254-261.
3. Bazzoli, F., R. M. Zagari, S. Fossi, P. Pozzato, G. Alampi, P. Simoni, S. Sottili, A. Ronda, and E. Ronda. 1994. Short-term low dose triple therapy for the eradication of Helicobacter pylori. Eur. J. Gastroenterol. 6:773-777.
4. Debets-Ossenkoppa, Y. J., A. J. Herscheida, R. G. J. Pota, E. J. Kuipersb, J. G. Kustersa, and C. M. J. E. Vandenbroucke-Graulsa. 1999. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands. J. Antimicrob. Chemother. 43:511-515.
5. Dore, M. P., A. Piana, M. Carta, A. Atzei, B. M. Are, I. Mura, G. Massarelli, A. Maida, A. R. Sepulveda, D. Y. Graham, and G. Realdi. 1998. Amoxycillin resistance is one reason for failure of amoxicillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol. Ther. 12:635-639.
6. Dore, M. P., D. Y. Graham, A. R. Sepulveda, G. Realdi, and M. S. Osato. 1999. Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins. Antimicrob. Agents Chemother. 43:1803-1804.
7. El-Omar, E. M., M. Carrington, W. H. Chow, K. E. L. McColl, J. H. Bream, H. A. Young, J. Herrera, J. Lissowska, C. C. Yuan, N. Rothman, G. Lanyon, M. Martin, J. F. Faumeni, Jr., and C. S. Rabkin. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398-402.
8. The European Helicobacter pylori Study Group (EHPSG). 1997. Current European concepts in the management of Helicobacter pylori infections. The Maastricht consensus report. Gut 41:8-13.
9. Graham, D. Y., G. M. Lew, H. M. Malaty, D. J. Evans, P. D. Klein, L. C. Alpert, and R. M. Genta. 1992. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102:493-496.
10. Grayson, M. L., G. M. Eliopoulos, M. J. Ferraro, and R. C. Moellering. 1989. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 8:888-889.
11. Han, S.-R., S. Bhakdi, M. J. Maeurer, T. Schneider, and S. Gehring. 1999. Stable and unstable amoxicillin resistance in Helicobacter pylori: should antibiotic resistance testing be performed prior to eradication therapy? J. Clin. Microbiol. 37:2740-2741.
12. Hua, J., H. C. Ng, K. G. Yeoh, K. Y. Ho, and B. Ho. 1998. Characterization of clinical isolates of Helicobacter pylori in Singapore. Microbios 94:71-81.
13. Kellenberger, E., A. Ryter, and J. Sechaud. 1958. Electron microscope study of DNA-containing plasmas. II. Vegetative and mature phage DNA compared with normal bacterial nucleotides in different physiological states. J. Biophys. Biochem. Cytol. 4:671-678.
14. Labenz, J., and G. Borsch. 1994. Evidence of the essential role of Helicobacter pylori in gastric ulcer disease. Gut 35:19-22.
15. Lamouliatte, H., R. Cayla, F. Zerbib, P. Talbi, and F. Megraud. 1995. Triple therapy using proton pump inhibitor-amoxicillin and clarithromycin for Helicobacter pylori eradication. Gut 37(Suppl. 1):A91.
16. López-Brea, M., D. Domingo, I. Sanchez, and T. Alarcon. 1997. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. J. Antimicroh. Chemother. 40:279-281.
17. López-Brea, M., M. M. Josefa Martínez, D. Domingo, and T. Alarcón. 2001. A 9-year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J. Antimicrob. Chemother. 48:295-297.
18. Luft, J. H. 1961. Improvements in epoxy resin embedding methods. J. Biophys. Biochem. Cytol. 9:409-414.
19. Mendonca, S., C. Ecclissato, M. S. Sartori, A. P. O. Godoy, R. A. Guerzoni, M. Degger, and J. Pedrazzoli, Jr. 2000. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 5:79-83.
20. Morshed, M. G., M. Karita, H. Konishi, K. Okita, and T. Nakazawa. 1994. Growth medium containing cyclodextrin and low concentration of horse serum for cultivation of Helicobacter pylori. Microbiol. Immunol. 38:897-900.
21. Nomura, A., G. N. Stemmermann, P. H. Chyou, G. I. Perez-Perez, and M. J. Blaser. 1994. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann. Intern. Med. 120:977-981.
22. Olivieri, R., M. Bugnoli, D. Armellini, S. Bianciardi, R. Rappuoli, P. F. Bayeli, L. Abate, E. Esposito, L. de Gregorio, and J. Aziz. 1993. Growth of Helicobacter pylori in media containing cyclodextrins. J. Clin. Microbiol. 31:160-162.
23. Osato, M. S., R. Reddy, S. G. Reddy, R. L. Penland, H. M. Malaty, and D. Y. Graham. 2001. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch. Intern. Med. 161:1217-1220.
24. Sipponen, P., and H. Hyvarinen. 1993. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand. J. Gastroenterol. 28(Suppl. 196):3-6.
25. Smith, S. I., K. S. Oyedeji, A. O. Arigbabu, C. Atimomo, and A. O. Coker. 2001. High amoxicillin resistance in Helicobacter pylori isolated from gastritis and peptic ulcer patients in western Nigeria. J. Gastroenterol. 36:67-68.
26. Torres, J., M. Camorlinga-Ponce, G. Pérez-Pérez, A. Madrazo-De la Garza, M. Dehesa, G. Gerardo González-Valencia, and O. Muñoz. 2001. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J. Clin. Microbiol. 39:2677-2680.
27. van Zwet A. A., C. M. J. E. Vandenbrouke-Grauls, J. C. Thijs, E. J. van der Wenden, M. M. Gerrits, and J. G. Kusters. 1998. Stable amoxicillin resistance in Helicobacter pylori. Lancet 352:1595-1596.
28. Webb, P. M., and D. Forman. 1995. Helicobacter pylori as a risk factor for cancer. Bailliere's Clin. Gastroenterol. 9:563-582.
29. Wolle, K., M. Nilius, A. Leodolter, W. A. Muller, P. Malfertheiner, and W. Konig. 1998. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur. J. Clin. Microbiol. Dis. 17:519-521.